Inclusion Criteria:  Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent Males and females age ≥ 18 years Patients with breast cancer, lung cancer, malignant melanoma or who have undergone stem cell transplant or chimeric antigen receptor (CAR) T cell therapy for a hematologic malignancy.  Other cancer types including hematologic malignancies may be allowed if they are receiving treatments outlined in section 4.1.4  Solid Tumor patients and those with hematologic malignancies: Currently receiving active anti-cancer therapy, or planned to start within 14 days, with intravenous cytotoxic chemotherapy (oral or intravenous), intravenous chemoimmunotherapy combination, immunotherapy alone, an oral CDK 4/6 inhibitor. (This does not apply to recipients of stem cell transplant and CAR T therapy) Therapy may be neo/adjuvant or for metastatic disease Eastern Cooperation Oncology Group (ECOG) Performance status (PS) of 0-2  Exclusion Criteria:  * Life expectancy of < 12 months